Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lanreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 known ✓ | P35346 | 16/20 | 1.00 |
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 1.00 |
| ▸ | SSTR3 | P32745 | 9/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 3/20 | 1.00 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanreotide SCHEMBL29402091 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19472556 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29356077 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14802383 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL19962799 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL14674691 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL29450601 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL21091289 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL22928940 | 1.00 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Lanreotide SCHEMBL28187023 | 0.99 | SSTR5 (0.99) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2025-09-11 | — | — | US | claimed |
| EP-4333874-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | Camurus AB (SE) | 2024-03-13 | — | — | EP | claimed |
| CN-117241822-A | Compositions and methods for treating neuroendocrine tumors | 卡姆拉斯公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2022235186-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | CAMURUS AB (SE) | 2022-11-10 | — | — | WO | claimed |
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | CAMURUS AB (SE) | 2026-05-28 | — | — | US | disclosed |
| CN-122074048-A | Methods of treating cancer | 诺华股份有限公司 | 2026-05-22 | — | — | CN | disclosed |
| WO-2026102005-A1 | FORMULATION OF WOUND DRESSINGS AND THE USES THEREOF | IONIC PHARMACEUTICALS, LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | disclosed |
| EP-4731247-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | Camurus AB (SE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260048203-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGE | KALEO, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260027303-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A MEDICAMENT CONTAINER | KALEO, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | disclosed |
| EP-4009936-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGE | Kaleo, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11338011-B2 | Method of treating diseases | AMRYT ENDO, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11324476-B2 | Systems and methods for automated fluid response measurement | 1929803 Ontario Corp. (CA) | 2022-05-10 | — | — | US | disclosed |
| US-11261215-B2 | Somatostatin prodrugs | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2022-03-01 | — | — | US | disclosed |
| US-20220054753-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGE | KALEO, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
| US-20220040413-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGE | KALEO, INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | SSTR5 6/4885SSTR2 12/4885SSTR3 10/4885 |
| US-11261215-B2 | Somatostatin prodrugs | VIP, SSTR4, SSTR5 | SSTR5 3/4885SSTR2 6/4885SSTR3 4/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | SSTR5 85/4885SSTR2 327/4885SSTR3 354/4885 |
| US-20250281569-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROENDOCRINE TUMORS | SSTR2, SSTR5, SSTR3 | SSTR5 2/4885SSTR2 1/4885SSTR3 3/4885 |
| US-20260048203-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A PREFILLED SYRINGE | SLC2A3, VMA21, CAPNS1 | SSTR5 1305/4885SSTR2 757/4885SSTR3 489/4885 |
| US-20260027303-A1 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES WITHIN A MEDICAMENT CONTAINER | MTREX, SLC2A4, SLC2A1 | SSTR5 931/4885SSTR2 1086/4885SSTR3 1207/4885 |
| US-20220042012-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | IGF2BP1, IGF2BP2, IGFBP1 | SSTR5 1274/4885SSTR2 1074/4885SSTR3 947/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | SSTR5 23/4885SSTR2 75/4885SSTR3 130/4885 |
| US-20260144852-A1 | COMPOSITIONS AND METHODS FOR TREATING ACROMEGALY | SSTR2, SSTR1, IGF1R | SSTR5 11/4885SSTR2 1/4885SSTR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.